Mr. Lalitkumar Pai, CEO of NKure and Dr. Mahendra Rao, Founder and Scientific Director of NKure, together with Mr. Suresh Ramu, Co-founder of Cytecare Hospital and Dr. Prasad Narayanan from Cytecare Hospital visiting Dr. Stanley Chang, Chairman of Medigen and Medigen team.
Medigen and NKure in collaboration to develop Medigen’s natural killer cell therapy (Magicell®-NK) in India.
Medigen Biotechnology Corp. (“Medigen”) has signed today (January 10, 2024) a collaboration agreement with the Indian company Nkure Therapeutics Private Limited (“NKure”), in which Medigen licenses its independently developed natural killer cell technology, named as Magicell®-NK, to NKure. This collaboration aims to initiate the application and commercialization of Magicell®-NK in the field of cancer in India.
Magicell®-NK refers to the NK cell therapy technology independently developed by Medigen. Through proprietary techniques, the number of NK cells are significantly expanded in vitro, and the cytotoxicity of NK cells are greatly enhanced. This technology has already received approval from the Taiwan Ministry of Health and can be used in various hospitals in Taiwan for cancer treatment. NKure is an innovative company in India specialized in natural killer cell therapy and has close collaborations with medical institutions such as Cytecare Cancer Hospital in India. After several months of discussions, Nkure decided to introduce Medigen’s Magicell®-NK technology to India, with the hope of using Cytecare Cancer Hospital as a trial center for conducting clinical trials using Magicell®-NK as a cancer treatment option in the future.
In 2020, India had approximately 1.32 million new cancer cases, ranking third globally after China and the United States. The number of cancer-related deaths was around 850,000, making India the second-highest globally in cancer-related mortality. Therefore, there is an urgent demand for various cancer treatment solutions, including cell therapy. Medigen and NKure anticipate that through this collaboration, combining their strengths in research and development, clinical expertise, and market promotion, they can jointly develop cell therapy technologies and products for the benefit of patients. The goal is to promptly provide effective treatment solutions for cancer patients in India.
Nkure Therapeutics Private Limited
NKure is an innovative Indian company specializing in natural killer cell therapy and engaged in the development of off-the-shelf NK cell therapy. The company’s mission is to scale up through technological innovation, providing affordable and more effective treatment methods for patients in India.
Official website: https://www.nkure.com/
Cytecare Cancer Hospital
Cytecare Cancer Hospital is a leading cancer care hospital located in the Karnataka state of India. It is equipped with advanced medical instruments, including Positron Emission Tomography/Computed Tomography (PET/CT). The hospital has a capacity of 150 beds, including 21 ICU beds, a bone marrow transplant center, and a laboratory accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL) in India. Cytecare Cancer Hospital offers various types of cancer treatments and is recommended as one of the best hospitals for treating cancer patients.
Official website: https://cytecare.com/